Figure 4. [²²⁵Ac]Pep-1L delays tumor progression, reduced tumor volume and tumor cell viability in vivo against GBMs.

In vivo bioluminescent imaging of mice bearing established fLuc-expressing U251 GBMs. (A) Mice infused with [²²⁵Ac]Pep-1L through CED (n = 8) showed reduced bioluminescence signal when compared to mice in control groups (n = 7) over a period of 29 days post infusion indicating delayed progression of established GBMs and reduced tumor cell viability upon therapy. (B) Quantification of bioluminescent signal showed that mice infused with [²²⁵Ac]Pep-1L had reduced tumor volumes when compared to mice in control groups. Data represented as means +/− SEM. Student's t-test showed significant difference between both the experimental groups (p < 0.01).